A far-reaching study shows just how much more effective CBD extracts are compared with traditional pharmaceutical solutions. We ran our own numbers, too, and the results were stunning!
My team has just pored through a far-reaching study into the effectiveness of CBD as a treatment for certain types of epilepsy.
And we were fascinated by what we found.
It turns out that a type of CBD called isolates required a far higher dosage than extracts to achieve the same effectiveness.
And when it comes to adverse effects like a change in appetite, drowsiness, and weight change, extracts proved far more preferable to patients.
Now, lower doses and fewer side effects is all well and good, but when you factor in the traditional pharmaceutical pricing model, the drug industry’s $1 trillion market is suddenly exposed to massive competition from over-the-counter CBD extracts.
I want to walk you through some important details.
Once I do, you’ll see why certain companies are best positioned to tap this $1 trillion market and reap the wealth-building profits that will follow…
The Drug Industry Is Pricing Itself Out of the Market
A research report published in Frontiers in Neurology examined the results of several studies on the effectiveness of CBD to treat certain types of “treatment-resistant” epilepsy. Some focused on CBD extracts as treatments while others looked at CBD isolates.
Extracts are notably different from isolates. CBD extracts retain all of the cannabinoids found in the cannabis flower – along with other vital molecules called terpenes. In isolates, these other cannabinoids and terpenes are stripped out, so they are just a pure form of CBD molecule.
After analyzing the report and studying the results, my team ran some numbers.
What they found was that CBD extracts provide an unpatentable advantage in effectiveness and price that will open up billions of dollars in profits – especially for well-positioned CBD health and wellness companies like this one, a company well-known to our Cannabis Investor’s Report members.
He was one of the first venture capitalists to see the amazing potential of the marijuana market. He’s personally helped mastermind some of the most successful cannabis IPOs in history. And now, in an urgent briefing, one of the world’s foremost authorities on cannabis IPOs just revealed how average investors can become true cannabis millionaires. Just click here to hear what he has to say.
That’s because treatment-resistant epilepsy is precisely the type of treatment for which Epidiolex – a CBD-based drug developed by U.K. drug company GW Pharmaceuticals PLC (NASDAQ: GWPH) – received FDA approval.
And since Epidiolex is a CBD isolate, it’s a great example of how pharmaceutical companies will price the treatments they develop. For a year’s worth of therapy, GW Pharmaceuticals will charge $1,235 per 100-milliliter bottle.
By way of comparison, we found 100-milliliter bottles of hemp extract that sell for around $165.
Once we adjust for milligrams of CBD in each bottle, the cost per milligram of CBD extract is one-quarter the cost per milligram of the CBD isolate in Epidiolex.
But that still doesn’t take into account the lower dosage required for CBD extracts. Once we do this, the cost falls by another factor of five.
The result is that pharmaceutical treatments like Epidiolex are nearly 20 times more expensive than over-the-counter CBD extracts.
As I told you last week, that’s not to say that all cannabis pharmaceutical solutions will fail. Our NICILytics database contains several analyst reports on pharmaceutical companies developing cannabis-based drugs, some of which show real promise.
But patients, and the insurance companies that pay the bills, have limits to what they are willing to pay.
Cheaper and Better Is Hard to Beat
Now whether extracts are 1/20th or 1/10th the price, CBD companies can offer an alternative that is much cheaper with far fewer side effects than pharmaceutical options.
And this is just one example of how CBD can replace traditional drugs. We believe this advantage reaches far beyond into many other treatments, in part because of the way nature designed it.
That’s why CBD is the one part of the cannabis plant that is showing the most medical promise right now.
And it won’t be long before everyone discovers just how high the pile of evidence reaches in favor of this powerful, unpatentable remedy.
When they do, you’ll want to be already invested in those cannabis stocks best set to breach Big Pharma’s substantial, and expensive, defenses.
Thanks for being an important part of the National Institute for Cannabis Investors,
Executive Director, National Institute for Cannabis Investors
PS: The Perfect Pot Portfolio. That’s what the paid-up members at Cannabis Investor’s Report are currently enjoying. Each of our flagship cannabis trades are currently up firmly in the green. But that’s just the start. With the markets continuing their boom this week, you’re going to want to learn the best ways to get into this market now before the next big surge hits. That’s why I’d like to make you a special offer today. You see, we’re gearing up to hand our Cannabis Investor’s Report readers our next cannabis play. And given the scope of the moneymaking potential in store, you’re definitely going to want to check this out. All you have to do is click here for all of the details.